JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M111996200 on April 3, 2002

J. Biol. Chem., Vol. 277, Issue 24, 21749-21758, June 14, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/24/21749    most recent
M111996200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calderwood, D. A.
Right arrow Articles by Ginsberg, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calderwood, D. A.
Right arrow Articles by Ginsberg, M. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Phosphotyrosine Binding-like Domain of Talin Activates Integrins*

David A. CalderwoodDagger , Boxu YanDagger , Jose M. de Pereda§, Begoña García Alvarez§, Yosuke FujiokaDagger , Robert C. Liddington§, and Mark H. GinsbergDagger

From the Dagger  Division of Vascular Biology, Department of Cell Biology, The Scripps Research Institute and the § Program on Cell Adhesion, The Burnham Institute, La Jolla, California 92037

Received for publication, December 17, 2001, and in revised form, March 4, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cellular regulation of the ligand binding affinity of integrin adhesion receptors (integrin activation) depends on the integrin beta  cytoplasmic domains (tails). The head domain of talin binds to several integrin beta  tails and activates integrins. This head domain contains a predicted FERM domain composed of three subdomains (F1, F2, and F3). An integrin-activating talin fragment was predicted to contain the F2 and F3 subdomains. Both isolated subdomains bound specifically to the integrin beta 3 tail. However, talin F3 bound the beta 3 tail with a 4-fold higher affinity than talin F2. Furthermore, expression of talin F3 (but not F2) in cells led to activation of integrin alpha IIbbeta 3. A molecular model of talin F3 indicated that it resembles a phosphotyrosine-binding (PTB) domain. PTB domains recognize peptide ligands containing beta  turns, often formed by NPXY motifs. NPX(Y/F) motifs are highly conserved in integrin beta  tails, and mutations that disrupt this motif interfere with both integrin activation and talin binding. Thus, integrin binding to talin resembles the interactions of PTB domains with peptide ligands. These resemblances suggest that the activation of integrins requires the presence of a beta  turn at NPX(Y/F) motifs conserved in integrin beta  cytoplasmic domains.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Integrin adhesion receptors are essential for the development and survival of multicellular animals. Normal functioning of the >20 human integrins often requires dynamic cellular regulation of integrin ligand binding affinity (integrin activation). Activation of integrins is important in many biological processes, including cell migration, hemostasis, extracellular matrix assembly, tumor metastasis, and the immune response (1, 2). Integrin alpha beta heterodimers generally possess two short cytoplasmic domains (tails). The integrin beta  tail plays a central role in the activation process, probably by undergoing regulated interactions with certain cytoplasmic proteins (1, 3).

Talin is an abundant and widely expressed 250-kDa integrin beta  tail-binding protein implicated in integrin activation (4). Talin is composed of a 50-kDa head and 205-kDa rod domain. The head domain contains a major integrin-binding site (5-7), and expression of a 1071-residue fragment of talin containing the head domain in cells leads to activation of integrin alpha IIbbeta 3 (5). The capacity of this fragment to activate integrin alpha IIbbeta 3 is lost when the head domain is deleted from it or when the beta 3 cytoplasmic domain is truncated (5). Talin binding to integrin beta  tails can be regulated via calpain proteolysis (6) or through the binding of phosphoinositides (8). Furthermore, the phosphorylation of either talin and/or integrin (9, 10) could provide additional mechanisms for regulation of integrin-talin interactions. Thus, the talin head domain is implicated in integrin activation, and modulation of its binding to integrins is likely to contribute to the regulation of integrin activation.

The talin head domain contains a predicted FERM domain (band four-point-one/ezrin/radixin/moesin homology domain) (11). FERM domains are found in a number of proteins and often mediate their interactions with the cytoplasmic domain of transmembrane proteins (12, 13). The crystal structures of the FERM domains from moesin, radixin, and band 4.1 (14-17) reveal a very similar overall fold. The FERM domain consists of a trefoil arrangement of three subdomains, each showing similarity to known domains. The first subdomain, F1 (using the nomenclature of Pearson et al. (17)), contains a five-stranded beta  sheet with an alpha  helix running across it and is similar to ubiquitin. The F2 subdomain is entirely alpha  helical with a short linker region and shows similarity to the acyl-CoA-binding protein. The F3 subdomain is a sandwich of two orthogonal antiparallel beta  sheets followed by an alpha  helix; this fold is found in a number of structures, including the phosphotyrosine-binding (PTB)1 and pleckstrin homology domains. In this study, we have localized a principal integrin beta  tail-binding site of talin to the predicted 96-residue PTB-like subdomain within the talin FERM domain and shown that expression of this PTB-like F3 subdomain leads to integrin activation. Furthermore, like other PTB domain ligands, the capacity of the beta 3 tail to bind the talin PTB-like domain depends on the integrity of a beta  turn-forming NPXY motif. These similarities between integrin binding to talin and PTB domain-ligand interactions suggest that activation of integrins by the talin PTB-like F3 subdomain requires a stable beta  turn at NPX(Y/F) motifs conserved in many integrin beta  cytoplasmic domains.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antibodies and cDNAs-- Anti-talin (8d4; Sigma), anti-hemagglutinin (12CA5; American Type Culture Collection), anti-Tac (7G7B6; American Type Culture Collection), anti-Syk (4D10; Santa Cruz Biotechnology), anti-Myc (Santa Cruz Biotechnology), and anti-GST (B14; Santa Cruz Biotechnology) monoclonal antibodies and anti-Dok polyclonal antibody (Santa Cruz Biotechnology) were obtained commercially. The anti-alpha IIbbeta 3 monoclonal antibodies PAC1 and anti-LIBS6 and the alpha IIbbeta 3-specific antagonist Ro43-5054 have been described previously (3). cDNAs encoding Tac-alpha 5, chicken talin-(186-435), mouse talin-(1-1071), mouse talin-(434-1071) (residue numbers refer to the sequences in Swiss Protein Database entry TALI_MOUSE (accession number P26039)), human Syk, Syk-(1-330) (entry KSYK_HUMAN (accession number P43405)), mouse Numb (entry NUMB_MOUSE (accession number Q9QZS3)), mouse Dok (entry TrEMBL (accession number P97465)), and alpha IIb, beta 3, and beta 3(Y747A) human integrin tail model proteins have been described previously (5, 18-22). cDNAs encoding mouse talin-(186-434), talin-(206-305) (F2), and talin-(309-405) (F3) were amplified by PCR and subcloned into the bacterial expression vector pGEX or the mammalian expression vector pcDNA3.1. The 5'-primer was designed to allow introduction of an N-terminal hemagglutinin tag during expression in mammalian cells. A cDNA for the mouse Dok PTB domain (amino acids 149-256; entry TrEMBL (accession number P97465)) was amplified by PCR and cloned into pCMV-Tag3 (Stratagene) to allow expression of an N-terminally c-Myc-tagged protein.

Purification of Recombinant Proteins-- Recombinant model proteins of integrin cytoplasmic tails and GST fusion proteins were expressed and purified as previously described (5, 19). Electrospray ionization mass spectroscopy revealed that integrin tail model proteins varied by <0.1% from the predicted molecular mass for the non-phosphorylated proteins (19). For surface plasmon resonance (SPR) experiments, GST was removed by addition of thrombin (~1 unit/mg of protein) and mixing overnight at room temperature. p-Aminobenzamidine beads (Sigma) and glutathione-Sepharose 4B beads (Amersham Biosciences) were then added to the mixture to remove the thrombin and GST. Proteins were dialyzed in running buffer (75 mM NaCl, 1.3 mM Na2HPO4, and 2.2 mM NaH2PO4, pH 7.4).

Affinity Chromatography with Recombinant Integrin Tails-- Affinity chromatography was performed using recombinant integrin tails bound to His-Bind resin (Novagen) as previously described (5, 6, 19). 5 µl of coated beads and 1 µg of purified GST fusion protein were routinely used. Bound proteins were fractionated by SDS-PAGE and analyzed by Western blotting.

SPR-- SPR analysis was performed as previously described using a BIAcore 3000 instrument (6). Briefly, sufficient streptavidin to generate an increase of ~500 resonance units was coupled to activated CM5 sensor chips (6). Recombinant beta 3 tails were biotinylated on a unique cysteine residue and immobilized on sensor chips via a biotin-avidin linkage (6). Tails were immobilized at a level previously determined to minimize mass transport artifacts. The binding of a range of concentrations of purified recombinant talin subdomains to the beta 3-coated chip was then analyzed. Analyte was injected using the KINJECT command specifying a 90 s association phase and a 40 s dissociation phase. Following completion of KINJECT, dissociation was followed for at least another 60 s. The use of KINJECT delays removal of the injection needle and so minimizes instrument noise at the start of the dissociation phase; however, a change in resonance units can be detected when the needle is removed following completion of the KINJECT dissociation phase 130 s after the start of the injection. The chip surfaces were regenerated with 2 M NaCl between experiments. All parameters were measured at a flow rate of 20 µl/min in running buffer.

Data Analysis-- Sensorgrams were analyzed, and rate constants were calculated as previously described (6). The kinetic data were interpreted in the context of a first-order kinetic model: A + B = AB (23-25). For such a model, the association (kon) and dissociation (koff) rate constants are described by Equation 1.


<UP>dAB/d</UP>t=k<SUB><UP>on</UP></SUB><UP>A · B</UP>−k<SUB><UP>off</UP></SUB><UP>AB</UP> (Eq. 1)
Equation 1 can be expressed with the parameters used in SPR analysis as follows (Equation 2),
<UP>d</UP>R/<UP>dt=</UP>k<SUB><UP>on</UP></SUB>C·R<SUB><UP>max</UP></SUB><UP>−</UP>(<UP>k<SUB>on</SUB></UP>C+k<SUB><UP>off</UP></SUB>)<UP> · R</UP> (Eq. 2)
where R is the response in resonance units at time t, Rmax is the maximum response at saturating concentrations of analyte, and C is the concentration of the analyte solution. Hence, the gradient of the dR/dt versus R plot, -ks, is described by Equation 3.
k<SUB>s</SUB>=k<SUB><UP>on</UP></SUB>C+k<SUB><UP>off</UP></SUB> (Eq. 3)
The dissociation rate constant value obtained from Equation 3 may not be reliable for low ranges (26); therefore, koff values were calculated from the dissociation phases of the sensorgrams using Equation 4,
<UP>ln</UP>(R/R<SUB>0</SUB>)=−k<SUB><UP>off</UP></SUB>(t−t<SUB>0</SUB>) (Eq. 4)
where R0 represents the response in resonance units at the start of dissociation, t0. The apparent equilibrium dissociation constant, Kd, was then determined from the ratio of these two kinetic constants (koff/kon). Kd was also calculated from Scatchard analysis of equilibrium binding using Equation 5,
R<SUB><UP>eq</UP></SUB>/C=R<SUB><UP>max</UP></SUB>/K<SUB>d</SUB>−R<SUB><UP>eq</UP></SUB>/K<SUB><UP>d</UP></SUB> (Eq. 5)
where Req is the response in resonance units at equilibrium.

FACS Analysis of the Activation State of alpha IIbbeta 3-- Chinese hamster ovary (CHO) cells expressing integrin alpha IIbbeta 3 (3) were transiently transfected with cDNAs encoding Tac-alpha 5 (1 µg) and talin fragments (3 µg) using LipofectAMINE Plus (Invitrogen). 24 h later, three-color flow cytometry was performed as described previously (3, 5). Briefly, cells were suspended and stained with PAC1 and then washed and stained with biotinylated anti-Tac monoclonal antibody 7G7B6. Bound PAC1 and 7G7B6 were detected with fluorescein isothiocyanate-conjugated goat anti-mouse IgM (BioSource, International) and streptavidin-conjugated R-phycoerythrin (Molecular Probes, Inc.), respectively. 5 min prior to analysis, propidium iodide (2 µg/ml final concentration) was added. Cells were washed and analyzed on a FACSCalibur instrument (BD PharMingen). PAC1 binding to live (propidium iodide-negative) transfected (7G7B6-positive) cells was assessed. alpha IIbbeta 3 activation was quantified as an activation index defined as (F - F0)/(Fmax - F0), where F is the median fluorescence intensity of PAC1 binding, F0 is the median fluorescence intensity of PAC1 binding in the presence of the alpha IIbbeta 3 antagonist Ro43-5054 (1 µM), and Fmax is the median fluorescence intensity of PAC1 binding in the presence of the alpha IIbbeta 3-activating monoclonal antibody anti-LIBS6 (2 µM). The percentage change in activation index (AI) following transfection was calculated as 100 × (AI - AI0)/(AI0), where AI0 = AI in cells transfected with the control vector.

Modeling of the Talin PTB-like Subdomain-- Three-dimensional homology models of the F3 subdomain of talin were made using the program Modeler 4 (27). Initial sequence alignments made with ClustalW (28) were manually edited to match the hydrophobic residues that constitute the core of the subdomain limiting the presence of insertions to the loops. The crystal structures of moesin, radixin, and band 4.1 (14-17) were used as templates independently or combined. The quality of the models was assessed with the program WHAT IF (29).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A 250-Amino Acid Fragment of the Talin Head Domain (Talin-(186-435)) Binds the beta 3 Tail and Activates Integrin alpha IIbbeta 3-- A talin fragment that contains the head domain (talin-(1-1071)), but not one that lacks the head domain (talin-(434-1071)), can activate alpha IIbbeta 3 integrins (5). To determine whether a portion of the talin head domain was sufficient for these functions, we analyzed a fragment of the talin head containing Glu186-Gln435 that binds to the integrin beta 1D tail (5). Talin-(186-435) bound to the beta 3 (but not alpha IIb) tail (Fig. 1A), and binding was inhibited by a Tyr-to-Ala mutation in the first NPXY motif, beta 3(Y747A) (Fig. 1A). This integrin-binding fragment of the head domain was sufficient to activate alpha IIbbeta 3 integrins in CHO cells (Fig. 1B). The magnitude of activation was comparable to that observed for the previously described talin-(1-1071) fragment (5) (mean increase in activation index = 76% (p = 0.001) versus 65% (p = 0.0003)). Furthermore, a fragment of talin that lacks this region (talin-(434-1071)) had no effect on the activation state of alpha IIbbeta 3 (mean change in activation index = 3%, p > 0.7) (Fig. 1B). The expression of talin-(186-435), talin-(1-1071), and talin-(434-1071) was confirmed in immunoblots of the transfected cells (data not shown). Thus, expression of a 250-amino acid beta 3 tail-binding fragment of the talin head domain is sufficient to induce alpha IIbbeta 3 activation.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Talin-(186-435) binds to beta 3 tails and activates integrin alpha IIbbeta 3. A, purified recombinant GST-talin-(186-435) was mixed with beads coated with recombinant beta 3 (lane 1), beta 3(Y747A) (lane 2), or alpha IIb (lane 3) cytoplasmic tails. Bound proteins were fractionated by SDS-PAGE, and GST-talin-(186-435) was detected by Western blotting with anti-GST antibodies. Loading of the recombinant integrin tails onto the beads was assessed by Coomassie Blue staining. Molecular mass markers (in kilodaltons) are indicated. B, CHO cells expressing alpha IIbbeta 3 were transfected with cDNA encoding talin-(186-435), talin-(1-1071), talin-(434-1071), or empty vector (3 µg) along with Tac-alpha 5 (1 µg) as a transfection marker. Cells were then harvested and analyzed by flow cytometry. Binding of the activation-specific anti-alpha IIbbeta 3 monoclonal antibody PAC1 to transfected cells (stained with anti-Tac antibody 7G7B6) was measured, and activation indices were calculated. Results represent mean increase in activation index ± S.E. (n = 6). *, p < 0.001 (Student's t test).

The Integrin-binding Fragment of the Talin Head Domain Contains the F2 and F3 Subdomains of the Predicted Talin FERM Domain-- As described above, we have localized an integrin-binding and -activating fragment of the talin head to residues 186-435. This fragment contains part of a predicted FERM domain (11). FERM domains are found in a large number of proteins; however, the overall sequence identity is often low (12, 13). BLAST analysis of the talin head domain revealed highly significant similarity to consensus FERM domain sequences (Conserved Domain Database sequences CD:pfam00373 and CD:smart-00295) generated using the Pfam and SMART programs (score 243, E = 2 × 10-65; and score 153, E = 2 × 10-38 , respectively). Individual BLAST comparison of the talin head domain with the sequences of crystallized moesin, radixin, and band 4.1 FERM domains demonstrated 25, 25, and 20% identities and 46, 47, and 37% similarities, respectively. These similarities establish significant (E = 4 × 10-10, 4 × 10-10, and 3 × 10-6, respectively) homology of this region of talin to these FERM domains. FERM domains are composed of three subdomains (F1, F2, and F3) (14-17). To identify the boundaries of the subdomains within the talin FERM domain, we aligned the talin head domain sequence with other FERM domains (Fig. 2). Superposition of the moesin secondary and tertiary structural elements (17) allowed us to predict that the mouse talin F2 subdomain extends from Ser206 to Leu305 and the F3 subdomain from Gly309 to Ser405 (numbered according to Swiss Protein Database entry TALI_MOUSE (accession number P26039)). Superposition of the moesin structure on multiple alignments of FERM domains generated by ClustalW (16) and hydrophobic cluster (12) analyses predicted very similar domain boundaries for the talin F2 and F3 subdomains. Therefore, three sequence alignments predicted identical boundaries for the talin F2 and F3 subdomains and indicated that talin-(186-435) contains all of the F2 and F3 subdomains, but only the last predicted beta  strand of the F1 subdomain. This suggested that the F2 and/or F3 subdomain might be responsible for beta  tail binding and integrin activation.


View larger version (108K):
[in this window]
[in a new window]
 
Fig. 2.   Sequence alignment of FERM domains. The primary sequences of eight FERM domain-containing proteins were aligned using the MultAlign program (46). Highly conserved (>90%) residues are shown in red, and less conserved (>50%) residues are shown in blue. Consensus symbols are as follows: ! is anyone of IV, % is anyone of FY, and # is anyone of NDQEBZ. The secondary structural elements of moesin (17) are indicated above the alignment (bars represent helices, and arrows represent beta  strands), and their localization within the F1 (purple), F2 (green), and F3 (orange) subdomains is color-coded. The start positions of talin fragments (residues 185, 206, and 309) are marked. The six highly conserved buried core FERM residues identified by Pearson et al. (17) are indicated (*).

The Isolated Talin F3 Subdomain Binds the beta 3 Cytoplasmic Tail with High Affinity-- As described above, a talin fragment containing both predicted F2 and F3 subdomains bound integrin beta  cytoplasmic domains. We therefore prepared individual F2 (talin-(206-305)) and F3 (talin-(309-405)) subdomains. Affinity chromatography revealed that both F2 and F3 subdomains bound the beta 3 tail (Fig. 3A). As observed for larger talin fragments, both F2 and F3 exhibited greatly reduced binding to the beta 3(Y747A) tail and almost undetectable binding to the alpha IIb tail (Fig. 3A). Both talin F2 and F3 subdomains also bound to the beta 1A and beta 1D integrin cytoplasmic tails, and binding was reduced by Tyr-to-Ala mutations in the first NPXY motif of these tails (data not shown). The binding was not due to a nonspecific interaction with the beta  tail, as purified GST did not bind (data not shown). Furthermore, removal of the GST moiety by thrombin digestion did not impair the ability of either the F2 or F3 subdomain to bind to beta 3 tails (see below). Thus, both predicted F2 and F3 subdomains of the talin FERM domain bound specifically to the beta 3 tail.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Talin F2 and F3 subdomains bind integrin beta  tails. A, beads coated with recombinant beta 3, beta 3(Y747A), or alpha IIb tail model proteins were incubated overnight with 1 µg of recombinant GST-talin F2 or F3. Bound proteins were fractionated by SDS-PAGE, and recombinant talin proteins were detected by Western blotting with anti-GST antibodies. Loading of the model proteins onto the beads was assessed by Coomassie Blue staining. Starting material represents 5% of the input material. B, the binding of talin subdomains to beta 3 tails was analyzed by SPR. Sensorgrams of the association and dissociation phases for talin F2 and F3 binding to beta 3 tails are shown. Talin subdomains at 50, 75, 125 and 200 nM were injected over a surface coated with ~480 resonance units (RU) of biotin-maleimide-modified beta 3 tail for 90 s at a flow rate of 20 µl/min. Similar results were obtained in three independent experiments.

We examined the real-time binding of each of these subdomains to the beta 3 tail by SPR. SPR analysis was performed using biotinylated beta 3 tail model proteins immobilized on a streptavidin-coated sensor chip (coupling level of 500 resonance units), and the data were analyzed in the context of a first-order kinetic model (A + B = AB) (6). These analyses revealed typical association and dissociation phases for both talin F2 and F3 subdomains (Fig. 3B). Under similar conditions, no binding of talin-(1-280) or talin-(1-186) was detected, consistent with their lack of interaction in affinity chromatography experiments (5) (data not shown). Furthermore, as previously observed for the talin head domain (6), neither the talin F2 nor F3 subdomain bound to streptavidin-coated chips lacking immobilized beta 3 ligand (data not shown). Data were analyzed using Equations 1-5, defined under "Experimental Procedures." The association rate constant kon was obtained from Equation 3 (Fig. 4B) using the association phase of the curve, and the dissociation rate constant koff was obtained from the dissociation phases of the sensorgrams using Equation 4 (23, 25). Using this method, rather than BIAevaluation software, the r2 values reported in Fig. 4 provide a measure of the goodness of fit (25). As recommended by the manufacturer (BIAcore, Uppsala, Sweden), data collected 10 s after injection start or stop were excluded from the analysis to avoid sample dispersion effects. At the ligand coupling level used, koff values (calculated from Equation 4) were independent of the concentration of analyte (talin F2 or F3 subdomain) used (Fig. 4A). This indicates negligible rebinding of analyte during the dissociation phase. Plots of ks versus analyte concentration (Fig. 4B) were also linear. This is consistent with a simple first-order interaction and facilitates calculation of kon from Equation 3. These analyses allowed us to calculate that talin F3 bound the beta 3 tail with a 4-fold higher affinity than talin F2 (Kd = 130 ± 10 and 540 ± 40 nM, respectively), primarily due to a markedly reduced on-rate for talin F2 ((3.9 ± 0.2) × 103 M-1 s-1) relative to F3 ((3.3 ± 0.1) × 104 M-1 s-1) (Table I). The dissociation constants (Kd) calculated using kinetic parameters are in good agreement with those calculated from equilibrium binding Scatchard plots using Equation 5 (Fig. 4C and Table I) and support a simple first-order interaction. The presence of the F2 subdomain does not notably enhance or inhibit talin binding to integrin beta  tails, as constructs containing the F2 and F3 subdomains retain the ability to bind beta  tails (Fig. 1A), and the isolated talin F3 subdomain binds the beta 3 tail with an affinity (Kd = 130 ± 10 nM) that is similar to that of the intact (F2 and F3 subdomain-containing) talin head domain (Kd = 91 nM) (6). Although the talin rod domain contains additional integrin beta  tail-binding sites (5, 30), the head domain binds with a 37-fold higher affinity than the rod domain (6), and the F3 subdomain binds with an affinity similar to that of the intact head domain. Therefore, the talin F3 subdomain contains a major integrin beta  tail-binding site.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Estimation of parameters for talin F2 and F3 binding to beta 3 tails. A, values of the dissociation rate constant koff calculated using Equation 4 are plotted against the concentrations of talin subdomains injected. Note that koff is independent of subdomain concentration. B, ks is plotted versus the concentration of talin subdomains injected. The slope of the line obtained by linear regression provides the estimate of the association rate constant kon (Equation 3). C, shown are the results from Scatchard analysis of equilibrium binding. The fitted values for the response at equilibrium (Req) are plotted versus the ratio Req/C. The slope of the line, estimated by linear regression, is equal to -1/Kd (Equation 5). RU, resonance units.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Kinetics of the binding of the talin F2 and F3 subdomains to integrin beta 3 tails
Talin F2 and F3 binding to beta 3 tails was measured by SPR, and the association (kon) and dissociation (koff) rates were calculated using Equations 1-4. The apparent equilibrium dissociation constant Kd was then determined from the ratio of these two kinetic constants (koff/kon) or from Scatchard analysis of equilibrium binding using Equation 5. Kinetic constants represent mean ± S.D.

The Talin F3 Subdomain Activates Integrins-- As described above, we narrowed an integrin-binding and -activating site in the talin head to a fragment containing the F2 and F3 subdomains and found that both subdomains can bind to the beta 3 tail. We therefore tested the ability of each subdomain to activate this integrin. To do this, we transfected alpha IIbbeta 3-expressing CHO cells with cDNAs encoding hemagglutinin-tagged talin F2 or F3 and measured binding of the activation-specific antibody PAC1 by flow cytometry. Cells transfected with talin F3 (as identified by surface expression of cotransfected Tac-alpha 5) exhibited increased PAC1 binding, resulting in a rightward tilt of the contour plot (Fig. 5A). A similar effect was observed for cells transfected with talin-(1-1071) (Fig. 5A). However, cells expressing talin F2 displayed a contour plot similar to that of cells transfected with empty vector or the non-activating talin-(434-1071) fragment (Fig. 5A). In all cases, the increased PAC1 binding could be completely inhibited by the alpha IIbbeta 3 antagonist Ro43-5054 (Fig. 5A and Table II). Calculation of the activation index of transfected cells indicated that expression of talin F3 resulted in alpha IIbbeta 3 activation (Fig. 5B). However, transfection of talin F2 resulted in PAC1 binding similar to that observed in cells transfected with empty vector or the non-activating talin-(434-1071) fragment (Fig. 5B and Table II). In all cases, the talin fragments were well expressed (Fig. 5C).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 5.   Expression of the talin F3 subdomain leads to activation of alpha IIbbeta 3. CHO cells expressing alpha IIbbeta 3 were transiently transfected with cDNA (1 µg) encoding Tac-alpha 5 along with cDNA (3 µg) encoding talin F2 or F3, talin-(1-1071), talin-(434-1071), or empty vector. The binding of PAC1 (activation-specific anti-alpha IIbbeta 3 monoclonal antibody) and 7G7B6 (to identify transfected cells) was then assessed by FACS analysis. A, shown are contour plots of cells stably expressing alpha IIbbeta 3 transfected with the indicated cDNAs in the absence or presence of the alpha IIbbeta 3 antagonist Ro43-5054. B, the activation indices of transfected cells were calculated as described under "Experimental Procedures," and the percentage change from cells transfected with empty vector is plotted (mean ± S.E., n = 9). *, p < 0.005 (Student's t test). C, the expression of recombinant talin subdomains in transfected CHO cells was examined by immunoblotting of SDS-PAGE-fractionated cell lysates (7 µg). HA, hemagglutinin.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Integrin activation by talin fragments
The geometric mean fluorescence intensity (MFI) of PAC1 binding to CHO cells expressing alpha IIbbeta 3 or alpha IIbbeta 3(Y747A) transfected with talin fragments or empty vector (3 µg) was measured by FACS analysis in the presence or absence of the alpha IIbbeta 3 antagonist Ro43-5054. Activation indices were calculated as described under "Experimental Procedures," and the percentage change from cells transfected with control vector was calculated. Results are expressed as mean ± S.E.

Mutations in an NPX(Y/F) motif that is conserved in most integrin beta  tails (31) inhibit integrin activation (3, 32). Such a mutation (beta 3(Y747A)) inhibited the binding of talin F3 (Fig. 3A) to integrin beta  tails and also inhibits the binding of intact talin (5). We therefore assessed the effect of this mutation on the capacity of talin F3 to activate integrin alpha IIbbeta 3. Integrin alpha IIbbeta 3 containing this mutation (alpha IIbbeta 3(Y747A)) was not activated by expression of talin F3 (Fig. 6 and Table II), although PAC1 binding could be induced by addition of the activating antibody anti-LIBS6 (Fig. 6A). Therefore, expression of the 96-amino acid F3 subdomain of talin (but not the F2 subdomain) activates integrin alpha IIbbeta 3, and this activation is inhibited by a mutation that disrupts the NPXY motif in the beta 3 cytoplasmic tail.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 6.   Mutation of the beta 3 NPXY motif blocks alpha IIbbeta 3 activation. CHO cells expressing alpha IIbbeta 3(Y747A) were transiently transfected with cDNA (1 µg) encoding Tac-alpha 5 along with cDNA (3 µg) encoding talin F2 or F3 or empty vector and analyzed as described in the legend to Fig. 5. A, shown are contour plots of cells transfected with the indicated cDNAs in the presence or absence of the alpha IIbbeta 3-activating antibody anti-LIBS6. B, the activation indices of transfected cells were calculated, and the percentage change from cells transfected with empty vector is plotted (mean ± S.E., n = 6). C, the expression of recombinant talin subdomains in transfected CHO cells was examined by immunoblotting of SDS-PAGE-fractionated cell lysates (7 µg). HA, hemagglutinin.

Talin F3 Is a PTB-like Domain-- The sequence similarity of talin to FERM proteins of known structure (see above) is sufficient to build a reliable three-dimensional homology model of the F3 subdomain of talin. The best model, as judged by the program WHAT IF (29), was obtained using the crystal structure of moesin (15, 17) as template (Fig. 7). The model has good structure packing quality (Z-score of -2.34) and distribution of hydrophobic residues to the interior/hydrophilic groups to the exterior of the folded domain (root mean square Z-score of 0.96), indicating that the PTB fold is compatible with the sequence of the F3 subdomain of talin. In the predicted structure, Val315, Leu330, Ile332, Val337, Val340, Ile348, Trp351, Leu353, Ile356, Phe366, Leu368, Phe370, Tyr377, and Val380 constitute a hydrophobic core enclosed by the packing of the two orthogonal beta  sheets, and the C-terminal amphipathic alpha  helix packs with the apolar side toward the beta  sandwich. This hydrophobic core is characteristic of the PTB/pleckstrin homology fold and contributes to its stability (33). The predicted PTB domain of talin lacks the long insertion between the beta 1 and beta 2 strands observed in the PTB domains of Shc (34), X11 (35), and Numb (36) and structurally is closer to the PTB domain of insulin receptor substrate-1 (IRS-1) (37) (Fig. 2D). C-alpha atoms of residues in the core of the domain superimpose with a root mean square deviation of 1.1 Å on the IRS-1 PTB domain structure. The PTB domain of IRS-1 binds ligands containing phosphorylated tyrosine in the NPXY motif; interaction with the phosphate group involves basic residues in the beta 4-beta 5 and beta 6-beta 7 loops. The PTB domain of talin does not contain basic residues in the equivalent phosphate-binding loops. Thus, talin appears to lack the structural requirements to recognize the phosphorylated form of NPXY motifs. Therefore, the talin F3 subdomain binds integrin beta  tails, activates integrins, and is predicted to be a PTB-like domain.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 7.   The talin F3 subdomain adopts a PTB-like fold. A, ribbon representation of the homology model for the F3 subdomain of talin; B, comparison of the F3 subdomain of talin (gray) with the PTB domain of IRS-1 (blue). Structures were aligned by superimposition of the beta  sheets. C-alpha atoms of residues in the core of the subdomain superimpose with a root mean square deviation of 1.1 Å. The ligand recognition site in IRS-1 is formed by the beta 5 strand, the beta 4-beta 5 and beta 6-beta 7 loops, and the alpha 1 helix. The figure was generated with MOLSCRIPT (47) and RENDER (48).

Activation of Integrins Is Not a General Property of beta 3 Tail-binding Proteins or PTB Domains-- Cellular expression of the beta 3 tail-binding talin F3 subdomain leads to integrin activation. This is not a general effect of beta 3 tail-binding proteins because talin F2, which also binds the beta 3 tail, does not result in activation. However, talin F2 binds beta 3 with a lower affinity than talin F3. Therefore, we tested whether expression of higher affinity beta 3 tail-binding proteins resulted in activation of alpha IIbbeta 3. The non-receptor tyrosine kinase Syk binds to the beta 3 tail via an N-terminal fragment containing the tandem SH2 (Src homology) domains (Syk-(1-330)). This fragment binds to the beta 3 tail with an ~5-fold higher affinity (Kd = 24 nM) than the talin F3 subdomain (20). When we transfected cells with either full-length Syk or its N-terminal integrin-binding fragment (Syk-(1-330)), there was no change in integrin activation (Fig. 8A). Expression of the transfected proteins was verified by Western blotting (Fig. 8C). Furthermore, because talin F3 is predicted to adopt a PTB-like fold, we also tested whether expression of other PTB domains resulted in integrin activation. Expression of the PTB domain-containing proteins Numb (22) and Dok (21) and the isolated Dok PTB domain did not significantly alter activation (Fig. 8B). Hence, activation of alpha IIbbeta 3 is neither a general property of beta 3 tail-binding proteins nor of PTB domains.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 8.   Activation of alpha IIbbeta 3 is not a general property of beta 3 tail-binding proteins or of PTB domains. A, the effect of expression of the beta 3 tail-binding protein Syk and the integrin-binding fragment of Syk (Syk-(1-330)) on alpha IIbbeta 3 activation was assessed as described in the legend to Fig. 1. Results are expressed as percentage change in activation index (mean ± S.E., n = 6). *, p < 0.003. B, the effect of expression of the PTB domain-containing proteins Numb and Dok and the isolated Myc-tagged Dok PTB domain on alpha IIbbeta 3 activation was assessed as described above. Results are expressed as percentage change in activation index (mean ± S.E., n = 6). *, p < 0.003. C, the expression of recombinant proteins in transfected CHO cells was examined by Western blotting of cell lysates (7 µg) with antibodies to Syk, Numb, Dok, or talin or to the Myc or hemagglutinin epitope tag.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Alteration of integrin binding affinity in response to intracellular signals (activation) is an important control mechanism for several integrin functions. Here, we report that a predicted PTB-like 96-amino acid subdomain of the talin FERM domain contains a major integrin-binding site and activates integrin alpha IIbbeta 3. PTB domains often recognize peptide sequences containing NPXY motifs (38). Mutations within an NPX(Y/F) sequence that is conserved in most integrin beta  cytoplasmic domains (31) inhibit talin interaction (5, 19, 39) and integrin activation (3, 32). The conservation of the NPXY motif, its role in talin binding, and its importance for integrin activation suggest that activation by the PTB-like domain of talin is a general property of talin-binding integrins and may require the presence of a beta  turn formed by the NPXY motif.

The talin head domain is predicted to contain a PTB-like subdomain within a putative FERM domain. FERM domains are found in a wide range of proteins, and the degree of sequence identity between FERM domains is often low (12). However, whereas the band 4.1 FERM domain exhibits only 30% sequence identity and 50% similarity to the moesin and radixin FERM domains, it is structurally very similar (root mean square deviation C-alpha superposition of <2.0 Å) (15). The presence of a FERM domain within talin has been proposed on the basis of primary sequence alignments performed using several different programs (11-13, 16), and comparison of the talin FERM domain with moesin or radixin reveals only slightly lower levels of identity and similarity (23% identity and 46% similarity, respectively) than seen for the band 4.1 moesin/radixin comparisons. Pearson et al. (17) identified six buried FERM residues that are highly conserved in FERM domains. Five of these six residues are identical in talin, whereas the one non-identical residue is a valine in place of a conserved glycine (Fig. 2). Together, these data suggest that the FERM fold is conserved in talin. FERM domains are composed of three subdomains (F1, F2, and F3), and the F3 subdomains adopt a PTB-like fold (14-17). Modeling the putative talin F3 subdomain by homology to the moesin structure indicates that the resulting fold has good structure packing quality and is similar to the IRS-1 PTB domain.

Loss-of-function mutations in the F3 module of known FERM domains are predicted to be within the hydrophobic core of the protein and are therefore likely to disrupt folding (15). Furthermore, known mutations that disrupt PTB domain-ligand interactions do not fall within residues conserved in talin (35-37). Thus, the identification of surface-exposed residues in talin that are involved in binding to integrins will require a structural analysis of the complex of the talin PTB domain with an integrin beta  tail. In this study, we have identified a 96-residue module of talin that binds and activates integrin alpha IIbbeta 3, whereas the previous minimal integrin-activating fragment of talin was a 1071-amino acid fragment of undefined structure. The structure and dynamics of the beta 3 cytoplasmic domain have been analyzed by NMR spectroscopy of model protein mimics of the beta 3 tail (40). The identification of the F3 subdomain as the fragment responsible for activation will enable an NMR analysis of a protein-protein interaction involved in integrin activation.

Our data suggest that the interaction of integrin beta  cytoplasmic domains with talin resembles the binding of a PTB domain to a peptide ligand in several ways. PTB domain-binding sequences, including NPXY motifs, form beta  turns when bound to a PTB domain (38). Consistent with such an interaction, the integrin beta 3 NPXY motif has the propensity to form a beta  turn (40), and this propensity is lost as a result of mutations of the NPXY motif that block both talin binding and integrin activation. Additional PTB domain-ligand interactions are provided by the amino acid sequence N-terminal to the beta  turn of the recognition motif (38). Consistent with such an interaction, minimal talin-binding peptides contain the conserved first NPXY motif of integrin beta 1A along with the preceding five amino acids (10, 39), providing additional similarities between the peptide binding properties of talin and authentic PTB domains. The integrin beta 3 tail does not adopt a stable beta  turn conformation in solution (40). However, its propensity to form a turn and its binding to the PTB-like F3 subdomain of talin suggest that a stable turn will be present when talin binds to integrins. We report here that the talin PTB-like F3 subdomain activates integrins, whereas certain other beta  tail-binding proteins do not. Furthermore, mutations that disfavor formation of a stable beta  turn block activation (3, 40). Hence, the integrin beta  tail-talin interaction bears many of the characteristics of PTB domain-ligand interactions, and the ability of the talin PTB-like F3 subdomain to activate integrins may require a stable beta  turn at the conserved NPX(Y/F) motif.

This study demonstrates NPXY-dependent ligand binding to the PTB-like FERM subdomain. Previous structural analyses have suggested that NPXY-dependent interactions of FERM domains could occur (17); however, this study represents the first experimental documentation of this principle (16). There are now 261 proteins in the non-redundant data base predicted to contain FERM domains (13). Thus, our studies may suggest a more general model for other FERM domain interactions. They may also suggest a facile means for identification of potential binding partners for FERM domains by the presence of beta  turn-forming NPXY and related (38) sequences.

PTB domains were initially characterized as domains that bind to phosphorylated tyrosines in the context of NPXY motifs (38). However, their binding is often independent of phosphotyrosine (36, 41, 42). The binding of talin or its PTB-like F3 subdomain to the integrin beta  tail does not require tyrosine phosphorylation of the integrin beta  tail because the bacterially expressed tail used in our binding assays was not phosphorylated. Indeed, tyrosine phosphorylation of the beta 1A NPXY motifs may inhibit talin binding (10). Furthermore, in our model of the talin PTB subdomain, basic donor groups that would coordinate the phosphate moiety are absent, suggesting that binding of the phosphorylated NPXY motif is energetically disfavored. Integrins are closely associated with talin at focal adhesions, stable attachments formed in relatively non-migratory cells. Tyrosine phosphorylation of the beta  tail leads to displacement of the integrin from these talin-rich structures (43). beta  tail tyrosine phosphorylation is also involved in integrin-dependent cell migration and induces binding of the PTB domain-containing protein Shc (44, 45). Hence, the tyrosine phosphorylation state of the integrin beta  tail may determine which PTB domain-containing beta  tail-interacting proteins associate with the integrin. These phosphorylation-regulated changes in PTB domain binding specificity may then be a molecular toggle switch that designates migration or stable focal adhesion formation in response to integrin-dependent adhesion.

    FOOTNOTES

* This work was supported by Grants HL-48728, HL-30915, and AR-27214 from the National Institutes of Health, and by the Susan G. Komen Breast Cancer Foundation, and the American Heart Association. This is Publication 13988-VB from the Scripps Research Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Cell Biology, Scripps Research Inst., CVN/Rm. 231, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 858-784-7124; Fax: 858-784-7343; E-mail: ginsberg@scripps.edu.

Published, JBC Papers in Press, April 3, 2002, DOI 10.1074/jbc.M111996200

    ABBREVIATIONS

The abbreviations used are: PTB, phosphotyrosine-binding; GST, glutathione S-transferase; SPR, surface plasmon resonance; FACS, fluorescence-activated cell sorter; CHO, Chinese hamster ovary; IRS-1, insulin receptor substrate-1.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hughes, P. E., and Pfaff, M. (1998) Trends Cell Biol. 8, 359-364[CrossRef][Medline] [Order article via Infotrieve]
2. Felding-Habermann, B., O'Toole, T. E., Smith, J. W., Fransvea, E., Ruggeri, Z. M., Ginsberg, M. H., Hughes, P. E., Pampori, N., Shattil, S. J., Saven, A., and Mueller, B. M. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 1853-1858[Abstract/Free Full Text]
3. O'Toole, T. E., Ylanne, J., and Culley, B. M. (1995) J. Biol. Chem. 270, 8553-8558[Abstract/Free Full Text]
4. Critchley, D. R. (2000) Curr. Opin. Cell Biol. 12, 133-139[CrossRef][Medline] [Order article via Infotrieve]
5. Calderwood, D. A., Zent, R., Grant, R., Rees, D. J., Hynes, R. O., and Ginsberg, M. H. (1999) J. Biol. Chem. 274, 28071-28074[Abstract/Free Full Text]
6. Yan, B., Calderwood, D. A., Yaspan, B., and Ginsberg, M. H. (2001) J. Biol. Chem. 276, 28164-28170[Abstract/Free Full Text]
7. Patil, S., Jedsadayanmata, A., Wencel-Drake, J. J., Wang, W., Knezevic, I., and Lam, S. C.-T. (1999) J. Biol. Chem. 274, 28575-28583[Abstract/Free Full Text]
8. Martel, V., Racaud-Sultan, C., Dupe, S., Marie, C., Paulhe, F., Galmiche, A., Block, M. R., and Albiges-Rizo, C. (2001) J. Biol. Chem. 276, 21217-21227[Abstract/Free Full Text]
9. Beckerle, M. C. (1990) Cell Regul. 1, 227-236[Medline] [Order article via Infotrieve]
10. Tapley, P., Horwitz, A., Buck, C. A., Duggan, K., and Rohrschneider, L. (1989) Oncogene 4, 325-333[Medline] [Order article via Infotrieve]
11. Rees, D. J., Ades, S. E., Singer, S. J., and Hynes, R. O. (1990) Nature 347, 685-689[CrossRef][Medline] [Order article via Infotrieve]
12. Girault, J. A., Labesse, G., Mornon, J. P., and Callebaut, I. (1999) Trends Biochem. Sci. 24, 54-57[CrossRef][Medline] [Order article via Infotrieve]
13. Schultz, J., Milpetz, F., Bork, P., and Ponting, C. P. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5857-5864[Abstract/Free Full Text]
14. Han, B. G., Nunomura, W., Takakuwa, Y., Mohandas, N., and Jap, B. K. (2000) Nat. Struct. Biol. 7, 871-875[CrossRef][Medline] [Order article via Infotrieve]
15. Edwards, S. D., and Keep, N. H. (2001) Biochemistry 40, 7061-7068[Medline] [Order article via Infotrieve]
16. Hamada, K., Shimizu, T., Matsui, T., Tsukita, S., and Hakoshima, T. (2000) EMBO J. 19, 4449-4462[CrossRef][Medline] [Order article via Infotrieve]
17. Pearson, M. A., Reczek, D., Bretscher, A., and Karplus, P. A. (2000) Cell 101, 259-270[CrossRef][Medline] [Order article via Infotrieve]
18. LaFlamme, S. E., Thomas, L. A., Yamada, S. S., and Yamada, K. M. (1994) J. Cell Biol. 126, 1287-1298[Abstract/Free Full Text]
19. Pfaff, M., Liu, S., Erle, D. J., and Ginsberg, M. H. (1998) J. Biol. Chem. 273, 6104-6109[Abstract/Free Full Text]
20. Woodside, D. G., Oberley, T. D., Leng, L., Wilsbacher, J. L., Miranti, C. K., Brugge, J. S., Shattil, S. J., and Ginsberg, M. H. (2001) Curr. Biol. 11, 1799-1804[CrossRef][Medline] [Order article via Infotrieve]
21. Noguchi, T., Matozaki, T., Inagaki, K., Tsuda, M., Fukunaga, K., Kitamura, Y., Kitamura, T., Shii, K., Yamanashi, Y., and Kasuga, M. (1999) EMBO J. 18, 1748-1760[CrossRef][Medline] [Order article via Infotrieve]
22. Dho, S. E., French, M. B., Woods, S. A., and McGlade, C. J. (1999) J. Biol. Chem. 274, 33097-33104[Abstract/Free Full Text]
23. Schuck, P. (1997) Annu. Rev. Biophys. Biomol. Struct. 26, 541-566[CrossRef][Medline] [Order article via Infotrieve]
24. Karlsson, R., Michaelsson, A., and Mattsson, L. (1991) J. Immunol. Methods 145, 229-240[CrossRef][Medline]